ArticleArchives of gynecology and obstetrics2025
Exposure to gonadotropin-releasing hormone agonist in early pregnancy leads to adverse pregnancy outcomes: a retrospective analysis.
Article in Archives of gynecology and obstetrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGnRH-a is commonly used in the luteal phase for pituitary down-regulation during in-vitro fertilization (IVF). There is an ineluctable risk of spontaneous pregnancy for infertile couples who lack the use of contraception during the luteal phase down-regulation before IVF treatment. However, it is unclear whether exposure to GnRH-a affects clinical pregnancy outcomes.
methodsA single-center retrospective cohort study based on propensity score matching was used to analyze the clinical data of a total of 6602 infertile women who were about to undergo assisted reproduction with IVF or intracytoplasmic microsperm injection with spermatozoa (ICSI) and with confirmed clinical pregnancies outcomes in the Reproductive Center of Sun Yat-sen Memorial Hospital, Sun Yat-sen University, China, from January 2011 to December 2022. Participants were divided into the NP group (Natural pregnancy with the use of GnRH-a) and the CT group (Conceived through IVF/ICSI-ET). Baseline characteristics and pregnancy outcomes of the groups were compared by correlation analysis, analysis of variance, and generalized estimating equations. The correlation between pregnancy outcomes and GnRH-a exposure was analyzed based on logistic regression modeling. The primary outcome of the study is the ectopic pregnancy rate. The secondary outcomes included spontaneous abortion rate, clinical pregnancy rate, live birth rate and adverse neonatal outcomes rate.
resultsOur study demonstrates statistically significant differences in spontaneous abortion rate (29.5% vs. 13.6%, P < 0.05), ectopic pregnancy rate (14.3% vs. 3.1%, P < 0.05), live birth rate ((56.2% vs. 83.3%, P < 0.05)) between NP group and CT group. Logistic analysis showed that exposure to GnRH-a was a risk factor for adverse pregnancy outcomes and was associated with spontaneous abortion(odds ratio[ OR], 95% confidence interval [95% CI] {2.66,1.61-4.40}, P < 0.05) and ectopic pregnancy(odds ratio [OR], 95%confidence interval [95% CI] {5.21,2.39-11.32}, P < 0.05).
conclusionExposure to GnRH-a during the luteal phase of down-regulation can adversely affect pregnancy outcomes. Therefore, we recommend contraception during the IVF/ICSI down-regulation. A higher dose of progesterone during early pregnancy is needed for infertile women who conceive spontaneously after exposure to GnRH-a.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.